Wednesday, 15 August 2018 - 12:14
  • it
  • de
  • en
  • fr

M&A

Bayer sells dermatology unit to Leo Pharma

Denmark-based Leo Pharma yesterday announced it had acquired Bayer’s dermatology unit. The acquisition covers a series of prescription products for the treatment of skin diseases such as acne (Skinoren), fungal infections (Travogen) and a significant number of topical steroid preparations…

UCB sold Innere Medizin to private equity

UCB has announced it has sold its German subsidiary Innere Medizin to private equity Paragon Partners. Innere Medizin employs 200 people and markets pharmaceutical specialties in German speaking countries. The parties have not provided the financial details of the transaction….

JnJ acquires natural OTC manufacturer Zarbee’s Naturals

Johnson & Johnson today has announced it has acquired Zarbee’s Naturals, a producer of natural OTCs for children, from private equity L. Catterton. Zarbee’s Naturals was founded in Utah in 2008 and sells natural OTCs: these are highly demanded products,…

GSK acquires part of 23andme for $300m to stimulate drug discovery

GlaxoSmithKline has announced today it has acquired part of the California-based biotech engineering company 23andme from investors Sequoia Capital and Google Ventures, plus some minor investors. As part of the agreement, GSK will pay $300m to access 23andme’s rich database,…

Novartis pays $1bn for Galapagos’ atopic dermatitis therapy

Novartis has announced it has acquired the rights to an atopic dermatitis treatment from Belgium-based Galapagos and Germany-based MorphoSys. The treatment, named MOR106, is a monoclonal antibody still undergoing clinical trials–a Phase II study was started in May 2018, but…

New mega-deal in pharma sector: PTC acquires Agilis for $945m

US-based PTC Therapeutics (New Jersey) yesterday announced, before trading started in Wall Street, that it had acquired Agilis Biotherapeutics (Cambridge, Massachusetts) for $945m. Agilis is a biotech developing gene therapies for rare diseases, especially central nervous system conditions. Agilis ’s…

Astellas exploring selling Europe assets for $500m

Bloomberg yesterday evening reported that Japan-based Astellas Pharma is exploring selling its Central and Eastern Europe assets, worth at least $500m. Astellas’ management has already hired Jefferies Financial investment banking firm to look for a buyer. According to the report,…

IHH gains control of Fortis Healthcare

Malaysia-based IHH has acquired 57% of India-based Fortis Healthcare for IR40bn ($583m). IHH has won against TPG–part of Manipal Health group–that had completed its due diligence itself and submitted an offer. Instead, no offer has come from neither a consortium…

FDA to approve new Valeant drug application

Today, at stock market opening, Valeant Bausch & Lomb’s subsidiary announced that FDA approved a new drug application for loteprednol etabonate ophthalmic gel 0.38%, aimed at treating post-operative eye inflammation. Once obtained definitive approval, it is likely to be quickly…

BMS hires banks to put French OTC division on sale (€1bn)

Reuters has reported that Bristol-Myers Squibb has hired Deutsche Bank and Jefferies to look for buyers of its French division producing and marketing OTCs, worth over €1bn. The French asset delivered sales of €425m in 2017 and has 1,500 employees….

Joint chairman appointed for Chinese groups Sinochem and ChemChina

A report published today has announced that Ning Gaoning, top Chinese chemical company Sinochem Group’s current chairman, will also become chairman of big Chinese competitor ChemChina. This is a clear indication that the Chinese government is willing to merge the…

News hint at $120bn-worth Sinochem-ChemChina corporate merger

According to news spread yesterday by Chinese media, China’s chemical titans Sinochem and ChemChina are likely to merge, thus creating a $120bn-worth company. It is important to note that such a merger could also be approved by Chinese government, since…

CVC gains control of Recordati for €3.03bn

It was announced yesterday evening that a consortium of investors led by private equity CVC had acquired from the Recordati family the Fimei SpA holding, which owns 51.8% of Recordati group. The heirs of Giovanni Recordati have earned €3.03bn thanks…

Sale of DSM Sinochem Pharmaceuticals to Bain Capital confirmed

It was confirmed yesterday evening that private equity Bain Capital had acquired DSM Sinochem Pharmaceuticals, a 50:50 joint venture between DSM and Sinochem Group, with 2,000 employees and sales of €440m in 2017. The deal includes an upfront €250 payment,…

Bain Capital to acquire DSM Sinochem Pharmaceuticals for €600m

Private equity Bain Capital, that yesterday morning announced the purchase of Italian Italmatch for €700m, is likely to close a new deal today and buy JV DSM Sinochem Pharmaceuticals (DSP) for €600m. DSP is a joint venture created in 2010…

Amazon buys online pharmacy for $1bn in widely expected move

Amazon has surprised the market by announcing its forthcoming acquisition of online pharmacy PillPack for $1bn. It was a widely expected move, so no wonder that the company’s shares have risen by 2.5% on the stock exchange. By buying PillPack,…

Italmatch Chemicals sold to Bain Capital for €700m

  According to news spread yesterday evening, Italian chemicals maker Italmatch Chemicals was sold for €700m from French investor Ardian to private equity firm Bain Capital. Bain Capital defeated rival bids from two competitors, i.e. private equity firms Cinven and…

Roche could be ready to acquire Tesaro ($2.7bn)

Roche’s shares yesterday rose over 2% (Zurich) as rumors started circulating that the Basel-based group is about to submit an offer to acquire US-based biotech Tesaro. Analysts and investors reportedly agree that Tesaro’s cancer portfolio could successfully integrate into Roche’s…

Merck & Co. could try to acquire Elanco (13.5bn)

Rumors on Merck & Co. targeting Eli Lilly’s Animal Health division Elanco are swirling. Eli Lilly last autumn announced it was planning to sell the asset, valued approximately $13.5bn by analysts.  Merck is already committed in the sector with Merck…

Recordati confirms talks with CVC

Fimei, the holding owning 51.18% of Recordati pharmaceutical group, has issued today a very short press release confirming ongoing talks with private equity CVC. The Recordati family, indeed, is planning to transfer to CVC its indirect control over the group….

Roche acquires full property of Foundation Medicine for $2.4bn

Switzerland-based Roche announced in a press release, before trading started in Europe, that it has completed the acquisition of Foundation Medicine (FD), of which it had acquired a majority stake (57%) over three years ago. Specifically, Roche has paid $2.4bn…

Coca Cola, Nestle and Kraft Heinz in talks with GSK

UK-based The Sunday Telegraph has reported today that The Coca-Cola Company, Kraft Heinz and Nestle have started negotiating with GlaxoSmithKline in order to acquire Horlicks. GSK last March informed the financial community that it was planning to dismiss the Horlicks…

Pfizer could seek acquisition in NASH business

Alongside the Health & Biotechnology Summit held in New York last week, rumors were circulated that Pfizer could be seeking to acquire assets in the Non-Alcoholic Steatohepatitis (NASH) business. NASH is nowadays among the most widespread conditions in the US…

NASH sector heats up

Bloomberg yesterday reported that biotech Madrigal Pharmaceuticals  is weighing a sale after some early talks with large pharmaceutical groups. The news has made Madrigal’s shares jump by over 150% in the last month. Madrigal is a biotech based in Pennsylvania,…